Broker laments ‘catastrophic negative surprise’ that highlights the risks with these types of ASX shares

ASX share Opthea Limited (ASX: OPT) remains suspended from trading as the biotech company works to avoid insolvency.

Opthea last traded at 60 cents per share.

Last week, we learned that Opthea has decided to cease development of its flagship sozinibercept (OPT-302) treatment.

OPT-302 had…